<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: The first therapeutic experiences with the conventional photosensitizer dihematoporphyrinester in the treatment of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> show the curative potential of photodynamic therapy (<z:chebi fb="7" ids="53228">PDT</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to test <z:chebi fb="0" ids="17549">5-aminolevulinic acid</z:chebi> (5-ALA)-induced <z:chebi fb="0" ids="15430">protoporphyrin</z:chebi> IX, a photosensitizer with a high mucosa specificity without phototoxic side effects on the skin, as a new form of <z:chebi fb="7" ids="53228">PDT</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Thirty-two patients (mean age, 68.5 years) with histologically proven high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (n = 10) and mucosal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (n = 22) in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> were treated </plain></SENT>
<SENT sid="3" pm="."><plain>Four to 6 hours after oral ingestion of 5-ALA (dose, 60 mg/kg body wt), irradiation was conducted with a dye laser system (635 nm) with a light dose of 150 J/cm2 </plain></SENT>
<SENT sid="4" pm="."><plain>The patients received 20-80 mg <z:chebi fb="14" ids="7772">omeprazole</z:chebi> daily after <z:chebi fb="7" ids="53228">PDT</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: High-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> was eradicated in <z:hpo ids='HP_0000001'>all</z:hpo> patients (10 of 10), and mucosal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was eliminated in 17 of 22 patients (77%) at a mean follow-up of 9.9 months (range, 1-30 months) </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> &lt; or = 2 mm in thickness were completely ablated (17 of 17) </plain></SENT>
<SENT sid="7" pm="."><plain>The method-related mortality and morbidity was 0% </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Severe <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and thin (&lt; or = 2 mm) mucosal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> can be completely ablated </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="7" ids="53228">PDT</z:chebi> might offer a minimally invasive treatment modality as an alternative to esophagectomy </plain></SENT>
</text></document>